Overview
The Quality Payment Program (QPP) is the CMS program created by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) to replace the Sustainable Growth Rate formula and shift Medicare Part B clinician payment from fee-for-service volume toward value and quality. It is the dominant regulatory vehicle driving value-based payment adoption in ambulatory Medicare.
QPP operates through two tracks. The Merit-based Incentive Payment System (MIPS) is the default track for clinicians who bill Medicare Part B above the low-volume threshold. Each eligible clinician earns a composite score 0–100 across four weighted performance categories: Quality (30%), Promoting Interoperability (25%), Improvement Activities (15%), and Cost (30%). The composite is compared to a performance threshold; scores above earn positive payment adjustments up to +9%, scores below face negative adjustments down to −9%, applied to Medicare Part B Physician Fee Schedule payments two years later on a budget-neutral basis.
The Advanced APM track is the alternative. Clinicians participating in Advanced Alternative Payment Models — those meeting criteria for risk-bearing arrangements (financial downside risk at or above specified thresholds) and quality measure reporting — are exempt from MIPS reporting and in earlier program years received a 5% APM Incentive Payment. Qualifying arrangements include Medicare Shared Savings Program Track 3 and ENHANCED, ACO REACH, Comprehensive Primary Care Plus, Oncology Care Model, and Bundled Payments for Care Improvement Advanced. For 2024 and beyond, CMS introduced MIPS Value Pathways (MVPs) as a partial transition to more specialty-focused reporting.
Operationally, QPP reporting depends on accurate Medicare Part B claims data, certified EHR technology (CEHRT) reporting, and for Improvement Activities, attestation of completed activities. Quality measures are pulled from multiple specification sets — MIPS Clinical Quality Measures, Qualified Clinical Data Registry (QCDR) measures, and CMS Web Interface measures. Measure selection is strategic: each practice must report on six Quality measures including at least one outcome or high-priority measure, and scoring depends heavily on benchmark achievement.
The financial stakes have grown substantially. At program inception in 2019, MIPS payment adjustments ranged ±4%; by 2024 performance year they scaled to ±9%. For a multispecialty group with $12M in Medicare Part B revenue, a ±9% adjustment is a ±$1.08M annual swing — large enough that most groups treat MIPS as a dedicated operational program with named owners, quarterly scorecards, and year-round gap-closure activities rather than an annual filing exercise.
The program has attracted significant criticism for complexity, measure proliferation, and limited evidence of clinical quality improvement. CMS has signaled ongoing evolution toward MVPs and eventually to a more streamlined set of specialty pathways. Strategic RCM leaders monitor annual QPP rule-making (published each November for the upcoming performance year) and adjust reporting strategy accordingly.
Industry benchmark
CMS QPP annual final rule (published November preceding performance year). 2025 performance threshold: 75 points. Performance year 2024 maximum adjustment: ±9%. CMS QPP participation data publicly released 9–12 months post-performance year.
Worked example
A 60-provider multispecialty group reports MIPS Quality via a QCDR. 2024 performance year composite: 82 points. Performance threshold: 75. Positive adjustment applies to 2026 Medicare Part B payments. With $8.4M annual Medicare Part B revenue and a roughly +4% payment adjustment, the group realizes approximately $336K in bonus payments in 2026 — net of approximately $80K in annual QPP reporting and gap-closure program cost.
Frequently asked questions — Quality Payment Program (QPP)
Who must participate in QPP?
Medicare Part B clinicians exceeding the low-volume threshold (currently $90K allowed charges, 200 Part B patients, 200 covered professional services). Those below the threshold are excluded. Clinicians in Advanced APMs are exempt from MIPS but track Advanced APM participation separately.
What's the difference between MIPS and Advanced APM?
MIPS is the default performance-reporting track with composite scoring across four categories. Advanced APM is the risk-bearing track: participating in a qualifying APM that meets CEHRT use, quality reporting, and financial risk criteria. Advanced APM participation historically carries a separate incentive and MIPS exemption.
What is a MIPS Value Pathway (MVP)?
MVPs are CMS's effort to streamline MIPS into specialty-focused reporting pathways. Each MVP includes a predefined set of Quality measures and Improvement Activities aligned to a clinical condition or specialty. MVPs are voluntary for performance years 2023–2025 and may become mandatory thereafter.
How does QPP relate to MACRA?
MACRA is the 2015 legislation; QPP is the CMS program implementing it. The two terms are often used interchangeably but MACRA is the statute and QPP is its regulatory implementation through annual final rule-making.
Disclaimer
This glossary entry is operational reference for revenue-cycle and medical-billing professionals. It is not legal, clinical, or contractual advice. Industry benchmarks cite named public sources where available; always verify against the current guidance from the authority body before relying on a number in a contract, policy, or compliance filing.